Early warning of intracranial tumors and epidemiological characteristics of viral hepatitis: from symptoms of increased intracranial pressure to prevention and control in high-incidence areas of hepatitis B.

Section 3 Brain Tumors I. Benign Brain Tumors Benign brain tumors refer to tumors that grow in a specific area within the skull (mostly outside the brain's nerve tissue), are well-differentiated, grow slowly, and are often curable, such as meningiomas, pituitary adenomas, embryonal remnant tumors, and vascular tumors. Malignant brain tumors, on the other hand (mostly growing within the brain's nerve tissue), are poorly differentiated, grow rapidly, and are difficult to cure, such as gliomas, metastatic tumors, and invasive tumors. Some benign brain tumors, due to their deep location and surrounding important structures, are already quite large when discovered, making complete surgical removal impossible and resulting in a poor prognosis. Conversely, some so-called malignant brain tumors, because they grow in less important brain tissue, can be almost completely removed, and patients can survive for a long time after surgery, sometimes even achieving a cure. In rare cases, brain tumors begin as benign but gradually transform into malignant ones. Therefore, regardless of the nature of the brain tumor, it should not be taken lightly; prompt medical attention is essential. II. Early Symptoms of Brain Tumors The cranial cavity is a nearly closed space. Normally, the space occupied by brain tissue, cerebrospinal fluid, and blood within the cranial cavity is relatively constant, keeping intracranial pressure within a normal range. If a brain tumor develops, it will increase intracranial pressure, clinically resulting in hypertensive intracranial pressure (HIP). The three main symptoms of HIP are headache, nausea and vomiting, and papilledema. Headache is the most common and earliest symptom. As the tumor grows gradually, the headache also changes gradually, initially mild, becoming more severe and persistent as the tumor grows. Nausea and vomiting can also be early symptoms of brain tumors. Once papilledema is found in the fundus, the tumor is already quite large. Besides HIP, another early symptom of brain tumors is caused by the tumor irritating and damaging brain tissue, most commonly manifesting as seizures, limb weakness and numbness, and unsteady gait. These symptoms vary depending on the location of the tumor. For example, tumors near the motor cortex often cause focal seizures or generalized tonic-clonic seizures. Tumors in the cerebellar hemispheres or cerebellar vermis cause gait instability. Some tumors located in the so-called "quiet area" of the brain-the frontal region-may not cause increased intracranial pressure or focal neurosis in the early stages, but patients may experience mental abnormalities such as anxiety, memory loss, poor concentration, and insomnia, which can easily be misdiagnosed as neurosis. Therefore, if a previously healthy person develops unexplained neurosis, headaches, or other symptoms, further examination is necessary to detect a brain tumor early. The incidence of brain tumors is 1 in 100,000 to 10 in 100,000. Primary brain tumors can occur in brain tissue, meninges, cranial nerves, pituitary gland, cerebral blood vessels, and embryonic remnants. Malignant tumors in other parts of the body can also metastasize to the brain, forming brain metastases. Clinical manifestations are often persistent headache, convulsions, nausea and vomiting, decreased or absent sensation in the limbs, ataxia and unsteady gait, decreased vision, papilledema, oculomotor dysfunction, lethargy, and personality changes. Depending on the location of the tumor, corresponding focal brain symptoms may appear, such as hemiplegia, sensory disturbances, aphasia, ataxia and visual field defects, acute altered consciousness, meningeal irritation, and increased intracranial pressure, such as severe headache, nausea, and projectile vomiting.

Chapter Six: Sub-health and Viral Hepatitis When the human body is in a sub-healthy state, its immune function is low, making it susceptible to infectious diseases. Viral hepatitis, in particular, is characterized by high infectivity, complex transmission routes, widespread prevalence, and high incidence, thus it is prevalent in my country. Section One: Epidemiology of Viral Hepatitis I. Introduction to Viral Hepatitis Viral hepatitis is a common infectious disease caused by various hepatitis viruses, characterized by high infectivity, complex transmission routes, widespread prevalence, and high incidence. Clinically, it mainly manifests as fatigue, loss of appetite, nausea, vomiting, hepatomegaly, and liver function impairment. Some patients may experience jaundice and fever, while others may develop urticaria, joint pain, or upper respiratory symptoms. my country is a country with a high prevalence of hepatitis, with viral hepatitis ranking first among legally managed infectious diseases. There are 120 million people infected with chronic hepatitis B virus alone. Chronic hepatitis B has a prolonged course; if not treated promptly, it can develop into cirrhosis and even liver cancer, seriously endangering human health. Only by adopting comprehensive prevention and control measures, primarily focusing on cutting off transmission routes, and protecting susceptible populations, can the incidence of disease be reduced. Viral hepatitis is a group of infectious diseases caused by various hepatitis viruses, primarily affecting the liver. Based on the causative virus, it can be classified into hepatitis A, hepatitis B, hepatitis C (or non-A, non-B hepatitis), hepatitis D, hepatitis E, hepatitis F, and hepatitis G. Viral hepatitis is highly contagious, with complex transmission routes and a wide spread. Hepatitis A and B have relatively high infection rates. The hepatitis B virus carrier rate is 10.09%. In recent years, hepatitis F and hepatitis G have also been discovered. II. The Prevalence of Hepatitis B in my country and the World Hepatitis B is an infectious disease caused by the hepatitis B virus (HBV), primarily affecting the liver and potentially causing damage to multiple organs. Hepatitis B is widespread globally, primarily affecting children and young adults, with a small percentage of cases progressing to cirrhosis or liver cancer. Therefore, it has become a serious global threat to human health and is currently one of the most prevalent and harmful infectious diseases in my country. Hepatitis B has no specific epidemic season and can occur year-round, but is mostly sporadic. In recent years, the incidence of hepatitis B has shown a significant increasing trend, mainly related to the prevalence, hygiene habits, living conditions, population immunity levels, and prevention and control measures. Generally speaking, the carrier rate of hepatitis B surface antigen (HBsAg) is higher in tropical regions than in temperate regions, higher in men than women, higher in children than adults, and higher in urban areas than rural areas, with significant differences in infection rates across different regions. North America, Western Europe, and Australia are low-prevalence areas, with HBsAg positivity rates of only 2%–5.0% and hepatitis B core antibody (anti-HBc) positivity rates of 4%–6%. Infection is rare in children and newborns. Eastern Europe, Japan, the Mediterranean region, Southwest Asia, and the CIS are moderate-prevalence areas, with HBsAg and anti-HBc positivity rates of 2%–7% and 20%–55%, respectively. Infection is relatively common in children and newborns. my country, Southeast Asian countries, and tropical Africa are high-prevalence areas, with HBsAg and anti-HBc positivity rates of 8%–20% and 70%–95%, respectively. Infection is extremely common in children and newborns. Epidemiological survey data from 1990 showed that about half of the population in my country had been infected with hepatitis B virus or was currently infected, and more than 10% of pregnant women were hepatitis B virus carriers. Without hepatitis B vaccination, 60% of newborns could be infected with hepatitis B within two years. Infants of mothers who are HBsAg positive typically have an HBsAg positivity rate of about 40% at 6 months of age; while infants of mothers who are both HBsAg and HBeAg positive have an HBsAg positivity rate of almost 90% to 100% at 6 months of age.